Company news

Prescient Therapeutics Limited news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Response to ASX Aware Letter

March 30, 2016

Reinstatement to Official Quotation - 19 November 2013

March 30, 2016

Intellectual Property Report Update

March 30, 2016

Virax Option to Acquire Exclusive Worldwide Licence

March 30, 2016

Virax Holdings Appendix 4E and 2014 Financial Report

March 30, 2016

VHL completes Pathway acquisiton, appoints new director

March 30, 2016

Disclosure Document

March 30, 2016

Co-X-Gene Development Pipeline

March 30, 2016

Appointment of Managing Director to Drive Cancer Programs

March 30, 2016

Appendix 4C - quarterly

March 30, 2016

US FDA Reactivates PTXs IND for PTX-100 Breast Cancer Trial

March 30, 2016

Two new Patents granted to Protect Lead Asset PTX-200

March 30, 2016

PTX Acquires Worldwide License for Cancer Biomarker p27

March 30, 2016

PTX-200 Phase 1B/2 Clinical Trial Update

March 30, 2016

Proposed Grant of Options to Non-Executive Directors

March 30, 2016

Prescient Therapeutics Granted Key U.S. Patents

March 30, 2016

Prescient Appendix 4E and 2015 Annual Report

March 30, 2016

March 2015 Appendix 4C - Quarterly

March 30, 2016

June 2015 Appendix 4C - Quarterly

March 30, 2016

IND for Phase 1b/2 Ovarian Cancer Trial Transferred to PTX

March 30, 2016

Encouraging Pre-Clinical Data Presented at US Cancer Meeting

March 30, 2016

December 2014 Appendix 4C - quarterly

March 30, 2016

Approval received to transfer IND Sponsorship for PTX-200

March 30, 2016

PTX-200 Breast Cancer Trial Progresses

February 16, 2016

Steven Yatomi-Clarke Appointed CEO

February 15, 2016

December 2015 Appendix 4C - Quarterly

February 11, 2016

Virax secures $3 million placement

February 10, 2016

Virax close out of VIR201 HIV Vaccine Phase IIa Trial

February 10, 2016

VIR201 HIV Vaccine Phase IIa Trial Results - 16 August 2010

February 10, 2016

Vhl to acquire deep AKT inhibitor portfolio

February 10, 2016

Update on VIR201 HIV Vaccine Clinical Trial - 9 August 2010

February 10, 2016

Transgene TG4010 Exclusive Option

February 10, 2016

Transgene Announces Topline Preliminary Results

February 10, 2016

SPP Fully Underwritten up to target amount of $1.03 million

February 10, 2016

September 2015 Appendix 4C - Quarterly

February 10, 2016

Prescient completes acquisition of AKTivate Therapeutics

February 10, 2016

Half Yearly Report and Accounts

February 10, 2016

FDA IND Re-Activation Request for Phase Ib/II Trial

February 10, 2016

FDA Allows PTX IND for Leukemia Phase Ib & II Trials

February 10, 2016

Eligible Shareholder Offer Document Mailing - 6 June 2011

February 10, 2016

Co-X-Gene Sub Licence and TG4001 - 24 February 2011

February 10, 2016

Convertible Notes - Quarterly Report - 29 January 2010

February 10, 2016

Capital Raising Update

February 10, 2016

Appendix 4E 30 June 2011

February 10, 2016

Appendix 4D - Half Year 31 December 2009

February 10, 2016

Additional Placement Raises $1.0 million

February 10, 2016

1 for 2 Rights Offer - 25 May 2011

February 10, 2016

← Newer news releases

Decks

The 5 newest of 44 decks. Every deck is listed under its year.